Jutta Ries1, Eleftherios Vairaktaris2, Rita Kintopp3, Christoph Baran3, Friedrich W Neukam3, Emeka Nkenke4. 1. Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany jutta.ries@uk-erlangen.de. 2. Department of Oral and Maxillofacial Surgery, University of Athens Medical School, Athens, Greece. 3. Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany. 4. Department of Oral and Maxillofacial Surgery, Halle University Hospital, Halle (Saale), Germany.
Abstract
BACKGROUND/AIM: Aberrant microRNA (miRNA) expression in blood of cancer patients is a common finding. The present study aimed at evaluating the differences in miRNA expression in whole blood samples of oral squamous cell carcinoma (OSCC) patients compared to healthy controls. MATERIALS AND METHODS: Microarray based miRNA profiling was performed on whole blood samples of 20 OSCC patients and 20 healthy volunteers and the differences in expression patterns between the two groups were evaluated. The results were validated by Reverse Transcription quantitative-Polymerase Chain Reaction (RT-qPCR) in 50 OSCC patients and 35 volunteers. RESULTS: 21 miRNAs were identified to be significantly differentially expressed in whole blood of OSCC patients compared to healthy controls. The impact of miR-186 (p=0.002), miR-494 (p=0.001) and miR-3651 (p=0.0001) could be validated by RT-qPCR. CONCLUSION: The aberrant expressions of miR-186, miR-494 and miR-3651 in whole blood of OSCC patients may serve as the basis for establishing minimally-invasive screening methods for OSCC based on miRNAs as biomarkers.
BACKGROUND/AIM: Aberrant microRNA (miRNA) expression in blood of cancerpatients is a common finding. The present study aimed at evaluating the differences in miRNA expression in whole blood samples of oral squamous cell carcinoma (OSCC) patients compared to healthy controls. MATERIALS AND METHODS: Microarray based miRNA profiling was performed on whole blood samples of 20 OSCC patients and 20 healthy volunteers and the differences in expression patterns between the two groups were evaluated. The results were validated by Reverse Transcription quantitative-Polymerase Chain Reaction (RT-qPCR) in 50 OSCC patients and 35 volunteers. RESULTS: 21 miRNAs were identified to be significantly differentially expressed in whole blood of OSCC patients compared to healthy controls. The impact of miR-186 (p=0.002), miR-494 (p=0.001) and miR-3651 (p=0.0001) could be validated by RT-qPCR. CONCLUSION: The aberrant expressions of miR-186, miR-494 and miR-3651 in whole blood of OSCC patients may serve as the basis for establishing minimally-invasive screening methods for OSCC based on miRNAs as biomarkers.